Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278338 | 0.87 | TDP1 (0.36) | TSHRTDP1ALDH1A1 | |
| SCHEMBL28346437 | 0.86 | CA12 (0.39) | CA12CA9TSHRKDM5AKDM4C | |
| SCHEMBL27873052 | 0.83 | TSHR (0.44) | TSHRKDM5AKDM4C | |
| Phenol SCHEMBL28090452 | 0.82 | ALOX5 (0.42) | CA12CA2CA9TDP1ALDH1A1 | |
| SCHEMBL11345617 | 0.81 | MAPT (0.32) | TDP1 | |
| SCHEMBL2221793 | 0.80 | — | — | |
| SCHEMBL154162 | 0.78 | CA12 (0.46) | CA12CA2CA9TSHRMAPK1 | |
| SCHEMBL375727 | 0.76 | CA12 (0.34) | CA12CA2CA9TSHRMAPK1 | |
| SCHEMBL28124857 | 0.74 | TSHR (0.34) | CA12CA9TSHRKDM5AKDM4C | |
| SCHEMBL375752 | 0.74 | CA12 (0.43) | CA12CA2CA9TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2777723-B1 | Implantable object comprising selectively degradable copolymers for improved explantability | BIOTRONIK AG (CH) | 2017-12-20 | — | — | EP | claimed |
| EP-2136851-B1 | A COATING OF FAST ABSORPTION OR DISSOLUTION | ABBOTT CARDIOVASCULAR SYSTEMS INC (US) | 2017-09-06 | — | — | EP | claimed |
| US-20140079742-A1 | COATING OF FAST ABSORPTION OR DISSOLUTION | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2014-03-20 | — | — | US | claimed |
| US-20140074224-A1 | COATING OF FAST ABSORPTION OR DISSOLUTION | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2014-03-13 | — | — | US | claimed |
| EP-2136851-A2 | A COATING OF FAST ABSORPTION OR DISSOLUTION | Abbott Cardiovascular Systems, Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| WO-2008076731-A2 | A COATING OF FAST ABSORPTION OR DISSOLUTION | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2008-06-26 | — | — | WO | claimed |
| US-20080145393-A1 | Coating of fast absorption or dissolution | ADVANCED CARDIOVASCULAR SYSTEMS, INC. | 2008-06-19 | — | — | US | claimed |
| JP-2008500104-A | — | — | 2008-01-10 | — | — | JP | claimed |
| EP-1755699-A1 | HEPARIN CONTAINING BLOCK COPOLYMERS COATED ON IMPLANTS LIKE STENTS | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005118018-A1 | HEPARIN CONTAINING BLOCK COPOLYMERS COATED ON IMPLANTS LIKE STENTS | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2005-12-15 | — | — | WO | claimed |
| US-20050266038-A1 | Antifouling heparin coatings | ADVANCED CARDIOVASCULAR SYSTEMS, INC. | 2005-12-01 | — | — | US | claimed |
| CN-117396497-A | Use of long acting growth hormone for the treatment of inflammation induced diseases | 阿森迪斯药物股份有限公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-109843295-B | Combination therapy with controlled release of CNP agonist | 阿森迪斯药物生长障碍股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-107405409-B | CNP prodrugs | 阿森迪斯药物生长障碍股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-109789189-A | Dosage regimen for controlled release of PTH compounds | 阿森迪斯药物骨疾病股份有限公司 | 2019-05-21 | — | — | CN | disclosed |
| WO-2005000894-A2 | BINDING MOLECULES FOR THE TREATMENT OF MYELOID CELL MALIGNANCIES | CRUCELL HOLLAND B.V. (NL) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004067569-A1 | INTERNALISING HUMAN BINDING MOLECULES AGAINST CD72 | CRUCELL HOLLAND B.V. (NL) | 2004-08-12 | — | — | WO | disclosed |
| CN-1419593-A | Adhesive system comprising etherified amino resins | AKZO NOBEL NV (NL) | 2003-05-21 | — | — | CN | disclosed |
| EP-1220657-A1 | LIPOSOME ENCAPSULATED SILVER SALT COMPOSITIONS | 1170535 Ontario Inc. (CA) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001026627-A1 | LIPOSOME ENCAPSULATED SILVER SALT COMPOSITIONS | 1170535 ONTARIO INC. (CA) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145393-A1 | Coating of fast absorption or dissolution | TNNC1, SLC10A2, SI | CA12 74/4885CA2 1650/4885CA9 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.